Coherus Oncology (CHRS) Other Non-Current Liabilities (2013 - 2026)

Coherus Oncology has disclosed Other Non-Current Liabilities across 14 years of filings, most recently posting $1.5 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.5 million, up 135.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (up 135.76% YoY), and the FY2025 annual result was $18.4 million, down 37.14% from the prior year.
• Other Non-Current Liabilities came in at $1.5 million for Q1 2026 at Coherus Oncology, down from $18.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $29.3 million in Q4 2024 to a low of $102000.0 in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $1.5 million (2025), against an average of $7.8 million.
• Across the five-year window, Other Non-Current Liabilities jumped 27053.92% in 2024 and sank 94.89% in 2025, its largest moves.
• Coherus Oncology's Other Non-Current Liabilities stood at $3.5 million in 2022, then jumped by 196.71% to $10.3 million in 2023, then surged by 185.11% to $29.3 million in 2024, then slumped by 37.14% to $18.4 million in 2025, then sank by 91.92% to $1.5 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.5 million (Q1 2026), $18.4 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.